ログイン 会員登録
icon_bulk_order一括注文 Acrobiosystems for English
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
phone
Your Position: ホーム > Cell > APP > CHEK-ATP081

HEK293/Human APP (GFP) Stable Cell Line

  • Description
    HEK293/Human APP (GFP) Stable Cell Line
  • Application

    Screening β-secretase and γ-secretase inhibitors which stops Aβ peptide formation.

  • Growth Properties
    Adherent
  • Selection Marker
    Hygromycin B (200 μg/mL)
  • Culture Medium
    DMEM medium + 10% FBS
  • Freeze Medium
    10% DMSO + 90% FBS
  • Quantity
    1 vial contains at least 5×10^6 cells in 1 mL serum-free cryopreservation medium
  • Storage
    Frozen in liquid nitrogen.
  • Mycoplasma Testing
    Negative
  • Sterility Testing
    Negative
  • Instructions for Use
    See data sheet for detailed culturing and assay protocol.
Bioactivity
 APP FACS

FACS analysis of APP (GFP) on HEK293/Human APP (GFP) Stable Cell Line.
HEK293/Human APP (GFP) Stable Cell Line was red line, negative control HEK293 cells was grey line (QC tested).

Bioactivity-Bioactivity CELL BASE
 APP CELL

HEK293/Human APP (GFP) Stable Cell Line (Cat. No. CHEK-ATP081) was treated with β-secretase (BACE1) inhibitor and γ-Secretase inhibitor (DAPT) inhibitor, the process of amyloid precursor protein(APP) metabolism by endogenous secretase was inhibited, and the result is shown as fluorescent aggregation of APP-GFP. A. DMSO. B. 10 μm β-secretase (BACE1) inhibitor. C. 10 μM γ -secretase inhibitor (DAPT). D. 5 μm β-secretase (BACE1) inhibitor + 5 μM γ -secretase inhibitor (DAPT) (Routinely tested).

Please contact us if you are interested in related cell pool service.

  • Background
    Amyloid precursor protein (APP) is  a type I integral membrane protein ubiquitously expressed in many tissues and concentrated in the synapses of neurons. The majority of APP is cleaved at the plasma membrane by the α-secretase in the non-amyloidogenic pathway.  The amyloidogenic pathway starts with β-secretase cleavage by BACE1 on the N-terminal part of the Aβ domain, releasing sAPPβ from a membrane-anchored fragment named βCTF or C103, which is subsequently cleaved by γ-secretase to release Aβ.
  • License Disclosure
    This cell line is provided for research use only. This license does not permit you to share, distribute, sell, sublicense, or otherwise make this cell line available for use to other laboratories, departments, research institutions, hospitals, universities, or biotech companies. The license does not permit modification of this cell line in any way. Inappropriate use or distribution of this cell line will result in revocation of the license. Modifications of this cell line, transfer to another facility, or commercial use of the cell lines may require a separate license and additional fees. AcroBiosystems does not warrant the suitability of this cell line for any particular use, and does not accept any liability in connection with the handling or use of this cell line.
  • Clinical and Translational Updates

コメント (0)


ETD of in-stock products: 4 business days

価格(JPY) : 980,000

プロモーション&展示



医薬品開発状況

  • Number of Launched Drugs:11 Details
  • Number of Drugs in Clinical Trials:39 Details
  • Latest Research Phase:Approved

データシート&ドキュメンテーション

関連製品一覧

新製品

お問い合わせ&コメント

This web search service is supported by Google Inc.

totopphone